CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Regarding metabotropic glutamate receptors, all three groups show antidepressant effects ... robust and sustained antidepressant effects of (R,S)-ketamine and esketamine. In addition, the breadth of ...

It works on the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor in the ... multiple treatments without relief. Spravato (esketamine) has been touted as a potential ...

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...

Increasing gamma-aminobutyric acid (GABA) and balancing glutamate, brain chemicals called neurotransmitters ... levels to rise but instead increase activity by stimulating receptors. GABA agonists ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

G protein-coupled receptors (GPCRs) are integral membrane proteins with seven membrane-spanning helices. Upon binding to a ligand – which can range from small molecules like cyclic AMP to ...

Background: Buspirone is a partial 5-HT 1A receptor agonist. Animal studies have shown that modulation of serotoninergic transmission at the 5-HT 1A receptor can induce analgesia in acute pain models.